November 6 is the day that could make or break Biogen.
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.